Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this combination treatment compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

Question 3

What kind of monitoring and tests will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for treatment and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any side effects I should be aware of with nivolumab and eribulin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer clinical trial (NCT04061863). Contact the study team or your healthcare provider for specific answers.

What this study is about